Novartis
Search results
Sandoz is a global leader in generic pharmaceuticals and biosimilars, with a mission to discover new ways to improve and extend people's lives. Learn more about our products, our quality standards, our innovation and sustainability efforts, and our partnerships and collaborations.
The company was founded in 1886 by Alfred Kern (1850–1893) and Edouard Sandoz (1853–1928) in Basel (Switzerland) under the name Chemiefirma Kern und Sandoz. Initially the company focused on production of dyes namely alizarin blue and auramine .
Oct 4, 2023 · Sandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company. The Sandoz AG headquarters plans to move to a landmark office building called “Elsässertor” in the center of Basel, right by the Basel SBB train station.
Oct 4, 2023 · Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off; Shares of Sandoz will be listed and commence trading today on the SIX Swiss Exchange; Spin-off allows shareholders to benefit from a Novartis with capital and management attention fully focused on innovative medicines
Sandoz | 923,890 followers on LinkedIn. Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally.
This report provides a comprehensive overview of Sandoz, including our business, strategy, governance and performance.
Aug 25, 2022 · Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the #1 European generics company and a global leader in biosimilars, and a more focused Novartis. Planned 100% spin-off would allow Novartis shareholders to participate fully in the potential ...
Oct 4, 2023 · Sandoz Group AG, the maker of copycat medicines, was spun off from drugmaker Novartis AG to begin life as a standalone company on Wednesday when its shares started trading on Switzerland’s stock...
Mar 5, 2024 · Basel, March 5, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Wyost ® (denosumab-bbdz) and ...
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally.
